NCT03417765 2024-10-24
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
VectivBio AG
Phase 1/2 Withdrawn
VectivBio AG
Indiana University
Institut Claudius Regaud
Children's Oncology Group
Tarix Pharmaceuticals
Tarix Pharmaceuticals
Johns Hopkins University
Roswell Park Cancer Institute
Roswell Park Cancer Institute
M.D. Anderson Cancer Center